|Axsome Therapeutics Inc., of New York||AXS-12||Norepinephrine reuptake inhibitor||Narcolepsy||FDA issued breakthrough designation|
|Diurnal Group plc., of Israel||Alkindi (hydrocortisone granules)||Steroid||Adrenal insufficiency||Ministry of Health in Israel approved the drug for infants, children and adolescents|
|Pharmacyte Biotech Inc., of Laguna Hills, Calif.||Cypcaps||Cell-in-a-box encapsulated cell product||Locally advanced, inoperable pancreatic cancer||FDA accepted the drug master file from manufacturing partner Austrianova|
|Revive Therapeutics Ltd., of Toronto||Bucillamine||Cysteine derivative||Mild or moderate COVID-19||FDA approved the start of the phase III, which is scheduled to begin in September|
For more information about individual companies and/or products, see Cortellis.